Table 3.
The distribution of (−)-[11C]2 and (−)-[11C]6 in Sprague Dawley control rats and rats pretreated using a σ ligand, YUN-143, or cold (±)-2 at 30 min postinjection
| Organ | (−)-[11C]2 | (−)-[11C]6 | |||
|---|---|---|---|---|---|
| Control | σ block | VAChT block | Control | VAChT block | |
| Blood | 0.309±0.017 | 0.339±0.075 | 0.271±0.093 | 0.162±0.009 | 0.170±0.014 |
| Lung | 1.045±0.091 | 0.928±0.199 | 0.927±0.319 | 0.701±0.065 | 0.782±0.055 |
| Liver | 2.448±0.272 | 1.962±0.306 | 2.234±0.258 | 1.455±0.091 | 1.048±0.698 |
| Spleen | 0.662±0.083 | 0.515±0.095 | 0.587±0.154 | 0.551±0.026 | 0.599±0.056 |
| Kidney | 0.785±0.119 | 0.751±0.093 | 0.770±0.113 | 0.854±0.051 | 0.892±0.057 |
| Pancreas | 1.200±0.105 | 0.799±0.133 | 0.764±0.075 | 0.694±0.192 | 0.577±0.018 |
| Muscle | 0.208±0.010 | 0.208±0.025 | 0.242±0.037 | 0.204±0.013 | 0.205±0.004 |
| Fat | 1.768±0.436 | 2.020±0.598 | 1.539±0.761 | 0.375±0.031 | 0.314±0.092 |
| Heart | 0.290±0.016 | 0.298±0.048 | 0.245±0.041 | 0.250±0.034 | 0.250±0.019 |
| Cerebellum | 0.317±0.047 | 0.216±0.020 | 0.214±0.062 | 0.223±0.016 | 0.207±0.020 |
| Brain stem | 0.437±0.039 | 0.293±0.037 | 0.276±0.048 | 0.257±0.019 | 0.236±0.020 |
| Thalamus | 0.370±0.043 | 0.280±0.036 | 0.234±0.038 | 0.275±0.008 | 0.235±0.025 |
| Striatum | 0.546±0.071 | 0.629±0.060* | 0.276±0.065** | 0.342±0.060 | 0.251±0.013*** |
| Cortex | 0.331±0.128 | 0.292±0.047 | 0.239±0.100 | 0.202±0.062 | 0.218±0.030 |
| Hippocampus | 0.350±0.042 | 0.288±0.020 | 0.220±0.058 | 0.222±0.025 | 0.237±0.014 |
| Total brain | 0.370±0.031 | 0.308±0.021 | 0.242±0.062 | 0.247±0.036 | 0.233±0.014 |
%ID/g values (mean ± SD) with n = 4 rats per group. p value was determined by using two-tailed paired Student’s t test for the striatum uptake in control rats versus rats pretreated with the blocking agent
p>0.05;
p=0.0014;
p=0.025